These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36816979)

  • 1. Editorial: Angiogenesis blockade for the treatment of gastrointestinal cancer.
    Passardi A; Bittoni A; Bai Z; Zhang Z; Sier C; He Y; Shahini E; Solimando AG
    Front Oncol; 2023; 13():1147849. PubMed ID: 36816979
    [No Abstract]   [Full Text] [Related]  

  • 2. A systematical comparison of anti-angiogenesis and anti-cancer efficacy of ramucirumab, apatinib, regorafenib and cabozantinib in zebrafish model.
    Wu JQ; Fan RY; Zhang SR; Li CY; Shen LZ; Wei P; He ZH; He MF
    Life Sci; 2020 Apr; 247():117402. PubMed ID: 32035930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies.
    Procaccio L; Damuzzo V; Di Sarra F; Russi A; Todino F; Dadduzio V; Bergamo F; Prete AA; Lonardi S; Prenen H; Palozzo AC; Loupakis F
    Drug Saf; 2019 Feb; 42(2):159-179. PubMed ID: 30649744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself.
    Yang QK; Chen T; Wang SQ; Zhang XJ; Yao ZX
    Angiogenesis; 2020 Aug; 23(3):279-298. PubMed ID: 32333216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-angiogenic therapies for gastric cancer.
    Hironaka S
    Asia Pac J Clin Oncol; 2019 Aug; 15(4):208-217. PubMed ID: 31111678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlling angiogenesis in gastric cancer: A systematic review of anti-angiogenic trials.
    Shan F; Miao R; Xue K; Li Z; Li Z; Bu Z; Wu A; Zhang L; Wu X; Zong X; Wang X; Li S; Ji X; Jia Z; Li Z; Ji J
    Cancer Lett; 2016 Oct; 380(2):598-607. PubMed ID: 26724681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiogenesis and lung cancer: ramucirumab prolongs survival in 2(nd)-line metastatic NSCLC.
    Das M; Wakelee H
    Transl Lung Cancer Res; 2014 Dec; 3(6):397-9. PubMed ID: 25806332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successes and failures of angiogenesis blockade in gastric and gastro-esophageal junction adenocarcinoma.
    Salati M; Caputo F; Bocconi A; Cerri S; Baldessari C; Piacentini F; Dominici M; Gelsomino F
    Front Oncol; 2022; 12():993573. PubMed ID: 36212393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer.
    Roviello G; Ravelli A; Polom K; Petrioli R; Marano L; Marrelli D; Roviello F; Generali D
    Cancer Lett; 2016 Mar; 372(2):187-91. PubMed ID: 26797419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression.
    Cai X; Wei B; Li L; Chen X; Liu W; Cui J; Lin Y; Sun Y; Xu Q; Guo W; Gu Y
    Int Immunopharmacol; 2020 Nov; 88():106858. PubMed ID: 32795895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Docetaxel and 5-FU enhanced the inhibitory effects of apatinib and ramucirumab on growth and migration of gastric cancer.
    Wu JQ; Fan RY; Zhai J; Li CY; Wei P; Shen LZ; He MF; Wang P; Huang XE
    Life Sci; 2022 May; 296():120439. PubMed ID: 35235851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in the treatment of solid tumors with apatinib: a systematic review.
    Zhao D; Hou H; Zhang X
    Onco Targets Ther; 2018; 11():4137-4147. PubMed ID: 30050305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety and efficacy of ramucirumab in combination with docetaxel in the treatment of lung cancer.
    Paulus V; Avrillon V; Pérol M
    Expert Rev Anticancer Ther; 2016 Nov; 16(11):1119-1129. PubMed ID: 27686510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study.
    Zhang Y; Xu J; Wang Q; Ling G; Mao Y; Cai M; Yang Y; Mei J; Han Z; Feng J; Wu Y; Shi L; Wen S; Shen B
    Ann Transl Med; 2022 Jun; 10(11):641. PubMed ID: 35813347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor progression-dependent angiogenesis in gastric cancer and its potential application.
    Hsieh HL; Tsai MM
    World J Gastrointest Oncol; 2019 Sep; 11(9):686-704. PubMed ID: 31558974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apatinib Inhibits Angiogenesis in Intrahepatic Cholangiocarcinoma by Regulating the Vascular Endothelial Growth Factor Receptor-2/Signal Transducer and Activator of Transcription Factor 3/Hypoxia Inducible Factor 1 Subunit Alpha Signaling Axis.
    Huang MP; Gu SZ; Huang B; Li GW; Xiong ZP; Tang T; Zeng SN
    Pharmacology; 2021; 106(9-10):509-519. PubMed ID: 34412054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apatinib inhibits tumor growth and angiogenesis in PNET models.
    Wu S; Zhou J; Guo J; Hua Z; Li J; Wang Z
    Endocr Connect; 2019 Jan; 8(1):8-19. PubMed ID: 30557852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer.
    Zhao S; Ren S; Jiang T; Zhu B; Li X; Zhao C; Jia Y; Shi J; Zhang L; Liu X; Qiao M; Chen X; Su C; Yu H; Zhou C; Zhang J; Camidge DR; Hirsch FR
    Cancer Immunol Res; 2019 Apr; 7(4):630-643. PubMed ID: 30755403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-angiogenic therapies for advanced esophago-gastric cancer.
    Fontana E; Sclafani F; Cunningham D
    Indian J Med Paediatr Oncol; 2014 Oct; 35(4):253-62. PubMed ID: 25538401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Latest Results for Anti-Angiogenic Drugs in Cancer Treatment.
    Frandsen S; Kopp S; Wehland M; Pietsch J; Infanger M; Grimm D
    Curr Pharm Des; 2016; 22(39):5927-5942. PubMed ID: 27426129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.